{
    "eid": "2-s2.0-85158052515",
    "title": "KEYNOTE-033: Randomized phase 3 study of pembrolizumab vs docetaxel in previously treated, PD-L1-positive, advanced NSCLC",
    "cover-date": "2023-08-01",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Oncology",
            "@code": "2730",
            "@abbrev": "MEDI"
        },
        {
            "@_fa": "true",
            "$": "Cancer Research",
            "@code": "1306",
            "@abbrev": "BIOC"
        }
    ],
    "keywords": [
        "immunotherapy",
        "NSCLC",
        "pembrolizumab",
        "programmed death 1",
        "programmed death-ligand 1"
    ],
    "authors": [
        "Shengxiang Ren",
        "Jifeng Feng",
        "Shenglin Ma",
        "Hua Jun Chen",
        "Zhiyong Ma",
        "Cheng Huang",
        "Li Zhang",
        "Jianxing He",
        "Changli Wang",
        "Jianying Zhou",
        "Pongwut Danchaivijtr",
        "Chin Chou Wang",
        "Ihor Vynnychenko",
        "Kai Wang",
        "Francisco Orlandi",
        "Virote Sriuranpong",
        "Ben Li",
        "Jun Ge",
        "Thao Dang",
        "Caicun Zhou"
    ],
    "citedby-count": 2,
    "ref-count": 26,
    "ref-list": [
        "Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries",
        "Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries",
        "Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer",
        "Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer",
        "Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer",
        "Pembrolizumab for the treatment of non-small-cell lung cancer",
        "Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial",
        "PD-1 blockade in advanced NSCLC: a focus on pembrolizumab",
        "Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial",
        "Structural basis for blocking PD-1-mediated immune suppression by therapeutic antibody pembrolizumab",
        "Structure of full-length human anti-PD1 therapeutic IgG4 antibody pembrolizumab",
        "Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer",
        "Randomized clinical trial of pembrolizumab versus chemotherapy for previously untreated Chinese patients with PD-L1-positive locally advanced or metastatic non-small-cell lung cancer: KEYNOTE-042 China study",
        "KEYNOTE-032: a randomized phase I study of pembrolizumab in Chinese patients with advanced non-small-cell lung cancer",
        "KEYNOTE-033: phase 3 study of pembrolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (NSCLC)",
        "Randomized, open-label phase III study of pembrolizumab (pembro) vs docetaxel (doce) in patients (pts) with previously treated NSCLC with PD-L1 tumour proportion score (TPS) \u22651%: KEYNOTE-033",
        "New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)",
        "Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN lung 200): an open-label, randomised, phase 3 study",
        "First-line crizotinib versus chemotherapy in ALK-positive lung cancer",
        "Development of a companion diagnostic PD-L1 immunohistochemistry assay for pembrolizumab therapy in non-small-cell lung cancer",
        "Combining immunotherapy and anticancer agents: the right path to achieve cancer cure?",
        "PD-L1 expression and survival among patients with advanced non-small cell lung cancer treated with chemotherapy",
        "Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced NSCLC: CheckMate 078 randomized phase III clinical trial",
        "Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial"
    ],
    "affiliation": [
        {
            "affiliation-city": "Bangkok",
            "@id": "60199575",
            "affilname": "Siriraj Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60199575",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Shanghai",
            "@id": "60129180",
            "affilname": "Tongji University School of Medicine",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60129180",
            "affiliation-country": "China"
        },
        {
            "affiliation-city": "Hangzhou",
            "@id": "60118432",
            "affilname": "The Second Affiliated Hospital Zhejiang University School of Medicine",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60118432",
            "affiliation-country": "China"
        },
        {
            "affiliation-city": "Hangzhou",
            "@id": "60118428",
            "affilname": "The First Affiliated Hospital, Zhejiang University School of Medicine",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60118428",
            "affiliation-country": "China"
        },
        {
            "affiliation-city": "Nanjing",
            "@id": "60073601",
            "affilname": "Jiangsu Cancer Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60073601",
            "affiliation-country": "China"
        },
        {
            "affiliation-city": "Guangzhou",
            "@id": "60069718",
            "affilname": "Guangdong Provincial People\u2019s Hospital of Southern Medical University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60069718",
            "affiliation-country": "China"
        },
        {
            "affiliation-city": "Hangzhou",
            "@id": "60029310",
            "affilname": "Zhejiang University School of Medicine",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60029310",
            "affiliation-country": "China"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60022183",
            "affilname": "King Chulalongkorn Memorial Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60022183",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Guangzhou",
            "@id": "60021182",
            "affilname": "Sun Yat-Sen University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60021182",
            "affiliation-country": "China"
        },
        {
            "affiliation-city": "Zhengzhou",
            "@id": "60018554",
            "affilname": "Zhengzhou University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60018554",
            "affiliation-country": "China"
        },
        {
            "affiliation-city": "Tianjin",
            "@id": "60017260",
            "affilname": "Tianjin Medical University Cancer Institute &amp; Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60017260",
            "affiliation-country": "China"
        },
        {
            "affiliation-city": "Sumy",
            "@id": "60016511",
            "affilname": "Sumy State University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60016511",
            "affiliation-country": "Ukraine"
        },
        {
            "affiliation-city": "Guangzhou",
            "@id": "60013156",
            "affilname": "Guangzhou Medical University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60013156",
            "affiliation-country": "China"
        },
        {
            "affiliation-city": "Rahway",
            "@id": "60007995",
            "affilname": "Merck &amp; Co., Inc.",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60007995",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Providencia",
            "@id": "127887073",
            "affilname": "Orlandi Oncologia",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/127887073",
            "affiliation-country": "Chile"
        },
        {
            "affiliation-city": "Beijing",
            "@id": "122400614",
            "affilname": "MSD China",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/122400614",
            "affiliation-country": "China"
        },
        {
            "affiliation-city": "Fuzhou",
            "@id": "121483016",
            "affilname": "Fujian Provincial Cancer Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/121483016",
            "affiliation-country": "China"
        },
        {
            "affiliation-city": "Shanghai",
            "@id": "113017334",
            "affilname": "MSD China",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/113017334",
            "affiliation-country": "China"
        },
        {
            "affiliation-city": "Kaohsiung",
            "@id": "109593237",
            "affilname": "Chang Gung Medical Foundation",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/109593237",
            "affiliation-country": "Taiwan"
        }
    ],
    "funding": [
        "Merck & Co.",
        "Merck Sharp & Dohme LLC"
    ]
}